The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design

summary

The gist

Generative models are increasingly used to propose molecules for drug discovery They can produce far more candidates than can be experimentally tested…

In short

Generative AI proposes many drug candidates, but static selection misses crucial dose and exposure data. Using PBPK simulations, researchers found that 85% of shortlisted molecules are outperformed by unselected ones because their required doses or safety margins are poor. This shows that accounting for how potency and pharmacokinetics combine is essential for finding viable drug leads.

Key concepts

Exposure-Aware Evaluation
This method assesses a molecule not just on its potency, but on the dose needed to reach the target and whether it remains safe at that dose. It combines predicted molecular properties with PBPK simulations to estimate actual drug exposure after oral dosing, allowing for a more realistic comparison of candidates.
Physiologically Based Pharmacokinetic (PBPK) Simulations
These are computer models that simulate how a drug moves through the body, including absorption, distribution, metabolism, and excretion. They estimate the free (unbound) drug concentration over time after oral administration. This simulation is crucial for determining the minimum effective dose and assessing safety at that specific exposure.
Minimum Effective Dose (MED)
The MED is the lowest oral dose required to keep the drug concentration above a certain threshold needed for target engagement throughout the dosing interval. It depends on both how potent a molecule is and its pharmacokinetic properties like absorption and clearance, meaning potency alone isn't enough.
Static Selection vs. Exposure-Aware Evaluation
Static selection ranks molecules based only on predicted molecular properties like potency and synthetic accessibility. Exposure-aware evaluation uses PBPK data to re-rank these candidates, revealing that static rankings can miss superior molecules because they don't account for how dose and exposure jointly determine success.

Terminology used across episodes

This episode discusses

The paper

The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design · Read on arXiv

Maria Franz, N. Benjamin Erichson

International Computer Science Institute

Transcript

Introduction to the show: ident: Genomics Radio. Generated commentary on the latest computational biology and genomics papers.

Ines: We're looking at the paper: "The Dose Makes the Poison".

Marcus: Here's the gist of the paper. Generative models are increasingly used to propose molecules for drug discovery They can produce far more candidates than can be experimentally tested, making computational selection essential This work investigates this gap by using physiologically based pharmacokinetic (PBPK) simulations to re-evaluate molecules selected from three PARP1-targeted generative pipelines Of 60 shortlisted molecules, seven fail to achieve sufficient target exposure, while 28% of the remaining candidates show predicted safety risks at their required dose Moreover, 85% of candidates with an achievable dose are outperformed by molecules overlooked during static selection These findings suggest that accounting for dose and exposure can substantially change which generated molecules are considered promising for drug development.

Ines: Exposure-Aware Evaluation Methodology We evaluate generated molecules based on the dose needed to achieve sufficient target exposure and the associated safety margins For each candidate, we combine predicted molecular properties with physiologically based pharmacokinetic (PBPK) simulations to estimate drug exposure following oral administration We then determine the dose required for target engagement and assess safety at that dose, accounting for uncertainty in both the molecular predictions and simulated exposure The minimum effective dose (MED) is determined by searching for the minimum oral dose at which the simulated free (unbound) drug concentration remains above this threshold during the dosing interval This MED depends on both potency and pharmacokinetics, as even a highly potent molecule may require a large dose if it is poorly absorbed or rapidly eliminated Safety at the required dose is assessed using the exposure-adjusted safety margin Mj = IC50j / Cj (d∗) This allows us to compare candidates based on their predicted behavior at a relevant dose.

Marcus: Pipeline Diversity and Static Selection We investigate three PARP1-targeted generative pipelines that differ in how they generate and optimize molecules These pipelines include MOOD, which is a docking-guided diffusion model without explicitly considering ADME during generation, REINVENT4-MPO, which is fine-tuned through reinforcement learning to optimize potency and ADME properties, and Mol2Mol, a seed-based approach that generates analogues of existing molecules Both REINVENT4-MPO and Mol2Mol are implemented using the REINVENT4 framework.

Ines: All generated molecules undergo the same filtering and ranking procedure, which involves applying hard filters for drug-likeness, synthetic accessibility, physicochemical properties, predicted ADME, structural alerts, mutagenicity, and predicted PARP1 activity The surviving molecules are then ranked using a weighted geometric mean (WGM) of static molecular desirability terms.

Paper summary: Ines: We just talked about how the paper investigates this gap between static property prediction and actual drug exposure requirements, focusing on molecules selected from three different PARP1-targeted generative pipelines Ines

Marcus: They found that out of sixty shortlisted molecules, seven failed to get enough target exposure, and twenty-eight percent of the rest showed predicted safety risks at their required dose Marcus

Yuki: It seems the core argument is that conventional property-based screening overlooks how those properties translate into actual drug exposure when you consider the necessary dose Yuki

Ines: The methodology involves using physiologically based pharmacokinetic simulations to estimate drug exposure after oral administration for each candidate and determining the minimum effective dose, or MED Ines

Marcus: They define this MED as the lowest oral dose where the simulated free drug concentration stays above a certain threshold during dosing intervals, which depends on both potency and pharmacokinetics Marcus

Yuki: And they also assess safety at that specific required dose using an exposure-adjusted safety margin, which they define as M j equals IC50 j divided by C j (d star) Yuki

Ines: This margin tells you if the predicted exposure is below the off-target inhibition threshold, and a larger margin is better Ines

Marcus: They used endpoint specific PBPK errors for uncertainty because they evaluate hERG and PARP2 using different parts of the concentration time profile Marcus

Yuki: They also show that eighty-five percent of candidates with an achievable dose were outperformed by molecules that were overlooked during the static selection phase Yuki <ref:2611.13398#pg1,of candidates with an achievable dose>

Ines: So, in short, the paper demonstrates that accounting for dose and exposure can significantly change which generated molecules are considered promising for drug development Ines

Marcus: It’s a shift from just looking at whether a molecule is potent to understanding its behavior under real-world dosing conditions Marcus

Conclusion: Ines: The paper, "The Dose Makes the Poison: Exposure-Aware Evaluation of Generative Drug Design," by Franz and Erichson, really pushes the idea that static selection criteria are insufficient when we talk about drug discovery Ines

Marcus: It shows that simply relying on predicted potency and toxicity doesn't capture how those properties combine to determine exposure at the dose needed for treatment, which is a crucial detail for any computational selection process Marcus

Yuki: What this means for us in population genetics is that we can’t just focus on the best single-molecule traits; we need to consider how those traits interact within a dosing scenario Yuki

Ines: The authors highlight that the usefulness of static off-target predictions depends entirely on how well they reflect risk at the exposure required for target engagement Ines

Marcus: So, future work needs to explore whether this disagreement between static ranking and exposure-aware outcomes persists across other targets and scoring strategies Marcus

Yuki: We need to see if this concept of dose-dependent risk holds up when we look at different biological systems or different experimental measurements Yuki

More episodes

← Home